Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome

CONTEXT: The programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) pathway is a key regulator in T-cell activation and tolerance, limiting effector T-cell function in peripheral tissues. Atezolizumab, an anti–PD-L1 monoclonal antibody, is approved for treatment of som...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzolla, Giulia, Coppelli, Alberto, Cosottini, Mirco, Del Prato, Stefano, Marcocci, Claudio, Lupi, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364624/
https://www.ncbi.nlm.nih.gov/pubmed/30746508
http://dx.doi.org/10.1210/js.2018-00366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364624/
https://www.ncbi.nlm.nih.gov/pubmed/30746508
http://dx.doi.org/10.1210/js.2018-00366

Ejemplares similares